Chiesi Farmaceutici, a family-owned international pharma company, has completed its $1.25 billion acquisition of rare disease-focused biopharma Amryt Pharma (Nasdaq:AMYT). The companies announced the deal in January and projected it would close in the first half of 2023. Strengthening Chiesi’s global rare disease focus Chiesi’s decision to acquire Amryt Pharma is part of a broader…